Apmonia Therapeutics and partners @GustaveRoussy and @CNRS will be presenting a poster at the 2023 @myESMO - European Society for Medical #Oncology #Gynecological #Cancers annual congress taking place 23-24 February in @barcelona_cat, Spain.
Apmonia Therapeutics
@ApmoniaTherap
Apmonia Therapeutics is a biotechnology company developing a pipeline of targeted therapies for a solid cancers, based on specific and selective targets
8 Following 18 Followers 6 Posts
Latest posts 5
Come and meet our CEO Albin JEANNE next week in Strasbourg at @BIOFIT_EVENT, the European marketplace for deals in life sciences.
Bel article sur @ApmoniaTherap et sa technologie dans @LesEchos
Merci @EYFrance pour cette mise en lumière
Nice article presenting @ApmoniaTherap and the company's technology in @LesEchos
Many thanks @EYFrance for this highlight
lesechos.fr/thema/articles…
#Cancer #oncology
Merci @EYFrance pour cette mise en lumière
Nice article presenting @ApmoniaTherap and the company's technology in @LesEchos
Many thanks @EYFrance for this highlight
lesechos.fr/thema/articles…
#Cancer #oncology
@ApmoniaTherap awarded “Scale-Up of the Year” (North of France) during @EYFrance Entrepreneur of the Year 30th ceremony
This price rewards ground-breaking innovation and the considerable potential of ourtechnological platform for delivering new therapies
#cancer #oncology
This price rewards ground-breaking innovation and the considerable potential of ourtechnological platform for delivering new therapies
#cancer #oncology
Apmonia Therapeutics announced in feb 2022 a 4 M€ fundraising round to complete regulatory preclinical studies of its anti-cancer immunotherapy drug candidate (AP-01)
Portfolio of therapeutic #peptides targeting #tumor microenvironment in solid tumors
apmonia-therapeutics.com/index.php/2022…
apmonia-therapeutics.com Apmonia Therapeutics announces a 4 M€ fundraising round | Apmonia Therapeutics Apmonia Therapeutics announces a 4 M€ fundraising round to complete regulatory preclinical studies of its anti-cancer immunotherapy drug candidate (AP-01). Portfolio of therapeutic #peptides targeting #tumor microenvironment in solid tumors
apmonia-therapeutics.com/index.php/2022…